In This Section

Mechanisms of Drug-Induced Liver Injury: From Bedside to Bench and Back

Saturday April 06, 2019

11:00 am - 1:00 pm Eastern Time (ET)

Room W206 B

DDD DMDD TOX TCP

Chair :

Neil Kaplowitz
Keck School of Medicine of USC

Xiaochao Ma
University of Pittsburgh



Drug-induced liver injury (DILI) remains one of the major concerns for drug developers, regulators, healthcare providers and patients. Unfortunately, the mechanisms of DILI are largely unknown. This symposium will highlight novel insights into the mechanisms of DILI from the perspectives of metabolomics, genomics, and cell signaling pathways. This session will also discuss the potential applications of novel findings from the preclinical studies of DILI for the management of DILI in the clinic.

Speakers

Neil Kaplowitz - Keck School of Medicine of USC

Novel Insights into the Role of Cell Signaling Pathways in Drug-Induced Liver Injury

Xiaochao Ma - University of Pittsburgh

Role of Human Pregnane X Receptor in DILI: Drug Metabolism and Beyond

Ann Daly - Institute of Cellular Medicine Newcastle University, UK

Genetic Associations in Drug-induced Liver Injury

Pranoti Mandrekar - University of Massachusetts Medical School

Translational Approaches to Develop Targeted Therapies in Liver Diseases

Liming Chen - University of Connecticut

Impact on Acetaminophen-induced Hepatotoxicity by Long Non-coding RNAs HNF1α-AS1 and HNF4α-AS1 in HepaRG Cells

Lan Zhang - University of Louisville School of Medicine

Lactobacillus rhamnosus GG Supernatant Prevents Acute Alcohol-induced Liver Steatosis and Injury through ER Stress and Autophagy-mediated Signaling Pathways

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019